VSTM verastem.com: יחס שווי פעילות לרווח לפני ריבית, מסים ופחת

Verastem, Inc. (VSTM) is implementing laboratory automation and software robots for trial analysis. The asset-light business model involves developing inhibitors in the US while outsourcing production. A team of elite scientists is motivated by the mission and investments. The EV/EBITDA multiple for this capital-intensive enterprise on the precise GURU.Markets chart shows that the current value is 0.00.

Verastem, Inc. (VSTM) development of inhibitors for specific mutations requires significant capital expenditures, making the calculation of enterprise value (EV) relative to operating profit (EBITDA) critical for analysis. The current EV/EBITDA trend for Verastem, Inc. (VSTM) allows investors to distinguish a fair premium for technological leadership in oncology from a dangerous asset overheat, thereby determining the optimal entry point for the stock.